For investors looking for a systematic way to find high-growth market leaders, the CAN SLIM method, created by William O’Neil, provides a disciplined structure. The approach mixes strict fundamental study with important technical signs to find stocks with solid earnings momentum, institutional support, and better price performance, preferably during good market periods. A recent filter using main CAN SLIM rules has identified Medpace Holdings Inc (NASDAQ:MEDP), a clinical research organization, as a possible candidate for more review.
Checking the Fundamental "CAN SLIM" Match
A close look at Medpace's finances shows a clear match with several parts of the CAN SLIM method. The company displays the strong earnings and sales growth that are the base of the system.
- Current Quarterly Earnings & Sales (The "C"): Medpace shows a quarterly earnings per share (EPS) growth of 27.2% and a revenue growth of 32.0% against the same quarter last year. This is much higher than the usual CAN SLIM limit of 18-20%, pointing to good recent business speed.
- Annual Earnings Increases (The "A"): The company's 3-year EPS compound annual growth rate (CAGR) is a notable 27.9%, easily above the 25% minimum growth wanted by the method. This shows a continued history of profit growth, not just a one-quarter jump.
- Leader in Profitability (The "L" - Quality Aspect): Medpace's Return on Equity (ROE) is very high at 98.3%, putting it at the peak of its field. A high ROE is a sign of an efficient, well-run company and is a key filter in CAN SLIM searches to tell leaders from others based on fundamental quality.
- Supply & Financial Health (The "S"): The company keeps a very clean balance sheet with a debt-to-equity ratio of 0.0. This lack of debt is a major positive, giving financial room and lowering risk, which fits with the system's liking for companies with solid financial states.
- Institutional Sponsorship (The "I"): Institutional ownership is noted at 84.9%, which is under the 85% limit often used in filters. This hints there is still space for more institutional purchases, a main force of demand that CAN SLIM investors watch carefully.
A full fundamental study supports this positive view, giving Medpace a high score based on excellent health and profit measures. The study mentions the company's strong growth outline together with a price that matches the wider market.
Reviewing Technical and Market Fit
While the fundamental argument is solid, the CAN SLIM system gives the same weight to technical and market points to choose possible investment times.
- Relative Strength (The "L" - Price Performance Aspect): Medpace's relative strength (CRS) is 75.5, meaning it has done better than about 75% of all stocks over the last year. This meets the common CAN SLIM filter rule for a lowest relative strength of 75, marking it as a market leader in terms of price action.
- Current Technical Position: The technical study shows a more detailed picture. While the stock's long-term action stays solid on a yearly basis, both its short-term and long-term directions are now rated as negative. The stock is trading in the center of its recent band and under important average lines, showing it is in a correcting stage instead of moving up to new highs.
- Market Direction (The "M"): This is a key point. The wider market, as shown by the S&P 500, is now showing a positive short-term direction but a negative long-term direction. CAN SLIM ideas strongly suggest looking for stocks that fit with the main market direction, meaning investors should be careful and choosy in such a split setting.
Summary and Plan Points
Medpace Holdings shows a clear fundamental picture for growth-focused investors, meeting several needs of the CAN SLIM method with its fast sales growth, excellent long-term earnings path, high profitability, and clear balance sheet. Its high relative strength confirms the market has seen this quality.
However, the present technical view adds a warning. The stock is not in a clear upward direction and is settling after a previous rise. For strict CAN SLIM followers, this would not be seen as a perfect "buy point," which usually needs a stock to be moving out of a good base shape on higher-than-normal volume. The present split market direction further shows the need for precise timing.
This study of Medpace shows the real use of the CAN SLIM filter. Investors can use this method to systematically find companies with solid growth histories and then use more technical study to find the best times to enter.
Find other stocks that pass this strict growth filter. You can see the full list of present candidates by going to the O'Neill CANSLIM High Growth screen.
,
Disclaimer: This article is for information only and is not financial advice, a suggestion, or an offer or request to buy or sell any securities. The study is based on given data and shows the author's view. Investing has risk, including the chance of losing the original amount. Always do your own research and think about talking with a qualified financial advisor before making any investment choices.
